Autolus Therapeutics (AUTL) Q4 2024 earnings summary

Executive summary

• Achieved FDA approval and commercial launch of AUCATZYL for adult relapsed/refractory B-cell ALL in November 2024, with 33 authorized US centers by March 2025, covering over 60% of the target population.

• Strategic collaboration with BioNTech and public financing added $600 million, significantly strengthening the cash position.

• AUCATZYL added to NCCN Guidelines, pivotal FELIX trial data published in NEJM, and no REMS requirement for use.

• Regulatory filings for obe-cel submitted in the UK and EU, with decisions expected in H2 2025; expansion into new indications including autoimmune diseases and pediatric ALL.

• Ongoing expansion into autoimmune diseases (CARLYSLE/SLE study) and pediatric ALL, with initial SLE Phase 1 trial dosing completed and data updates planned.

Financial highlights

• Year-end 2024 cash, cash equivalents, and marketable securities totaled $588 million, up from $239.6 million at end-2023, mainly due to BioNTech deal and equity raise.

• Net loss for 2024 was $220.7 million, compared to $208.4 million in 2023; loss from operations was $241.4 million.

• R&D expenses rose to $138.4 million (from $130.5 million), and SG&A expenses increased to $101.1 million (from $46.7 million), reflecting commercialization investments.

• FY 2024 net revenue was $10.1 million, a significant increase from $1.7 million in FY 2023.

• Received a $30 million milestone payment from Blackstone and made a £10 million regulatory milestone payment to UCLB.

Outlook and guidance

• Well-capitalized to support US, UK, and EU launches and pipeline development, with cash runway through key data milestones.

• Targeting 60 authorized US centers by end of 2025, aiming to reach 90% of the target patient population.

• Regulatory decisions for obe-cel in the UK and EU expected in H2 2025.

• Updates on CARLYSLE (autoimmune/SLE) and pediatric studies expected in H2 2025, with long-term follow-up data and an R&D event in April 2025.

• No sales guidance for 2024 due to ramp-up variables; focus on reporting patients dosed and revenue recognized.